GenSci048

Phase 2Small molecule

Changchun GeneScience Pharmaceutical Co., Ltd.

GenSci048 is one of 51 small molecule programs targeting Connective Tissue Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Connective Tissue DiseaseActive, not recruiting

EndometriosisActive, not recruiting

Connective Tissue DiseasePhase 2

Active, not recruiting

EndometriosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

199 competitors in Endometriosis

#DrugCompanyPhaseTrials

Orilissa

AbbVie

Phase 3

16 2

Revia

Teva

Phase 3

1 3

Lupron

AbbVie

Phase 3

1 4

Leuprorelin

Takeda

Phase 3

8 5

Lupron

EEastern Cooperative Oncology Group

Phase 3

1 6

Firmagon

Ferring

Phase 3

1 7

Trental

VValidus Pharmaceuticals

Phase 3

1 8

Estradiol/norethindrone Acetate

AbbVie

Phase 3

5 9

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

1 10

EE20/DRSP(BAY86-5300)

Bayer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Connective Tissue Disease

NCT06189495

Q1 2030

Phase 2Recruiting

Endometriosis

NCT06963177

Clinical

Trials by Indication[1]

Connective Tissue Disease1 trial

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease

Recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT06189495·30 enrolled

Endometriosis1 trial

A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

Recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT06963177·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for GenSci048. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GenSci048 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GenSci048. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Changchun GeneScience Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Changchun GeneScience Pharmaceutical Co., Ltd.

GenSci048

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2030

Trials by Indication[1]

Connective Tissue Disease1 trial

Endometriosis1 trial

References

Drug Info

Quick Facts

Related News